Drug Profile
Research programme: CD4 antagonists - Consensus Pharmaceuticals
Latest Information Update: 15 Sep 2006
Price :
$50
*
At a glance
- Originator Consensus Pharmaceuticals
- Class
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 15 Sep 2006 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 19 Apr 2002 Preclinical trials in HIV infections treatment in USA (unspecified route)